Articles tagged with: Dacetuzumab

News»

[ by | Sep 26, 2012 11:37 am | Comments Off ]
New Agents In Combination With Revlimid Show Promise For Relapsed / Refractory Multiple Myeloma

Treatment strategies that com­bine Revlimid with newer types of anti-tumor agents may be ef­fec­tive for re­lapsed and re­frac­tory mul­ti­ple myeloma, ac­cord­ing to myeloma experts who reviewed re­­sults from stud­ies of these new com­bi­na­tions.

Refractory and re­lapsed mul­ti­ple myeloma is notoriously dif­fi­cult to treat. For every remission period that is achieved, relapse typ­i­cally arises sooner and with greater re­sis­tance to pre­vi­ously used ther­a­pies. These patients have lim­ited op­tions for ther­apy.

In examining trials that tested new ther­a­pies in com­bi­na­tion with Revlimid (lena­lido­mide), the authors of the review hoped to find the po­ten­tial …

Read the full story »

NewsFlash »

[ by | Feb 18, 2010 3:17 pm | Comments Off ]

Dacetuzumab Shows Some Potential For Multiple Myeloma – Results from a Phase 1 clinical trial show that dacetuzumab (SGN-40), an anti-CD40 monoclonal antibody, has some anti-myeloma effects. The best response observed during the trial was stable disease in 20 percent of patients. The study authors found that doses up to 12 mg/kg per week were well tolerated. Most side effects were mild to moderate and included fatigue, headache, nausea, and anemia. The study authors suggest that dacetuzumab may produce better response rates in combination with other myeloma drugs. Two combination trials (one with Revlimid (lenalidomide) and one with Velcade (bortezomib)) are underway.  For more information, please see the study in The Haematologica Journal (pdf) and the clinical trial descriptions (dacetuzumab with Revlimid or Velcade) .

Myeloma Awareness Month Teleconference Series – Each Friday during the month of March, the International Myeloma Foundation (IMF) will be hosting a teleconference to raise awareness and provide up-to-date information about multiple myeloma. The teleconferences are scheduled for 7 p.m. EST and will include a 60 minute presentation followed by a 30 minute Q&A. Patients, family members, caregivers, and health care professionals are welcome to join. Please see the IMF Web site for more information.

NCI Designs MGUS/Smoldering Myeloma Study – Researchers from the National Cancer Institute (NCI) are in the process of developing a prospective study with the goal of identifying causes of transformation from monoclonal gammopathy of undetermined significance (MGUS) and smoldering myeloma (both asymptomatic, pre-malignant disorders) to multiple myeloma. The study will enroll 350 patients with MGUS or smoldering myeloma in the United States and follow them for up to five years. For more information, please contact the research nurse for this study, Mary Ann Yancey, at (301) 435-9227 or yanceym@mail.nih.gov.

For a more detailed listing of myeloma related events, please check the Myeloma Beacon Events Calendar.

NewsFlash »

[ by | Apr 29, 2009 12:44 am | Comments Off ]

MMRF ‘Laugh For Life’ Fundraising Event — On May 5, the Multiple Myeloma Research Foundation (MMRF) will host the ‘Laugh For Life’ fundraiser in New York City from 6 p.m. to 9 p.m.  The event will feature dinner, live and silent auctions, and an entertaining line up of stand-up comedians.  More information, as well as ticket purchase, may be found at the MMRF Web site.

Dacetuzumab Clinical Trials Currently Enrolling — Seattle Genetics, Inc. has announced preclinical data for dacetuzumab, an anti-CD40 monoclonal antibody currently being tested for treatment of multiple myeloma and non-Hodgkin's lymphoma. In the most recent results, dacetuzumab enhanced patient response to regimens of conventional chemotherapeutic agents, and researchers have identified a tumor mutation that helps predict which patients will respond to dacetuzumab. Two clinical trials, the first testing dacetuzumab alone and the second testing it in conjunction with Revlimid (lenalidomide) and dexamethasone (Decadron), are currently enrolling. For more information, see the Seattle Genetics, Inc. preclinical results press release.

Sign Up With LLS’s 'Team In Training' For The Nation’s Triathlon – On September 13, the Leukemia & Lymphoma Society (LLS) will host the Nation’s Triathlon, the only triathlon dedicated to fighting blood cancer, in Washington, D.C.  Although the event is already sold out, individuals can still participate by joining LLS’s 'Team in Training' (TNT) program. By signing up with TNT, participants will receive four to five months of certified coaching, race gear, and travel and lodging arrangements. For more information, see the LLS Team in Training Web site.

For a more detailed listing of myeloma-related events, please check the Myeloma Beacon Events Calendar.